AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
48.21
-2.05 (-4.08%)
Oct 1, 2026, 2:06 PM EDT - Market open
AnaptysBio Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, AnaptysBio stock has a consensus rating of "Strong Buy" and an average price target of $88.5. The average 1-year stock price forecast is 83.57% higher than the current stock price, while the lowest is $70 (+45.20%) and the highest is $140 (+190.40%).
Price Target: $88.5 (+83.57%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for AnaptysBio stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 8 | 8 | 7 | 5 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 11 | 10 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| J.P. Morgan | J.P. Morgan | Buy Reiterates $70 → $60 | Buy | Reiterates | $70 → $60 | +24.46% | Sep 30, 2026 |
| Leerink Partners | Leerink Partners | Buy Maintains $90 → $81 | Buy | Maintains | $90 → $81 | +68.01% | Sep 23, 2026 |
| Barclays | Barclays | Buy Maintains $75 | Buy | Maintains | $75 | +55.57% | Sep 23, 2026 |
| UBS | UBS | Buy Reiterates $76 | Buy | Reiterates | $76 | +57.64% | Sep 22, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $95 | Buy | Reiterates | $95 | +97.05% | Sep 22, 2026 |
Financial Forecast
Revenue This Year
125.15M
from 234.60M
Increased by 17.97%
Revenue Next Year
171.31M
from 106.09M
Increased by 36.88%
EPS This Year
4.35
from -0.46
EPS Next Year
5.07
EPS and Forward PE are based on non-GAAP adjusted numbers.